Is it even worth investing in ASX blue chips these days?
Jaz Harrison
August 17, 2020
ASX blue chips have attracted investors for decades. But are
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
ASX blue chips have attracted investors for decades. But are
The S&P/ASX 200 (INDEXASX: XJO) is set to open flat
The S&P/ASX 200 (INDEXASX: XJO) is expected to take a
The Avita Therapeutics Inc (ASX: AVH) share price was trading
What a month it was for the S&P/ASX 200 (INDEXASX:
The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower
The S&P/ASX 200 (INDEXASX: XJO) is expected to jump this
CSL (ASX:CSL) has announced a US$450 million acquisition to the
The chief financial officer (CFO) of CSL (ASX:CSL) has left
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
